Magle Chemoswed Holding Valuation

Q: What is the Fair Price of 52X when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

52X (€2.94) is trading below our estimate of [[fair value]] (€11.53)

Is 52X undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 52X when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 52X (€2.94) is trading below our estimate of fair value (€11.53)

Significantly Below Fair Value: 52X is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 52X?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 52X. This is calculated by dividing 52X's market cap by their current preferred multiple.
What is 52X's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	SEK 680.87m

52X key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.2x
Enterprise Value/EBITDA	19.5x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 52X's PE Ratio compare to its peers?

The above table shows the PE ratio for 52X vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	23.8x
GXI Gerresheimer	23.8x	21.7%	€2.7b
1SXP SCHOTT Pharma KGaA	29.7x	15.9%	€4.5b
2FJ0 Pierrel	29.9x	n/a	€92.8m
2INV 2invest	11.8x	n/a	€59.2m
52X Magle Chemoswed Holding	40.7x	n/a	€680.9m

Price-To-Earnings vs Peers: 52X is expensive based on its Price-To-Earnings Ratio (40.7x) compared to the peer average (23.8x).

Price to Earnings Ratio vs Industry

How does 52X's PE Ratio compare vs other companies in the European Life Sciences Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	26.4%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	26.4%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: 52X is good value based on its Price-To-Earnings Ratio (40.7x) compared to the European Life Sciences industry average (41.5x).

Price to Earnings Ratio vs Fair Ratio

What is 52X's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

52X PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	40.7x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 52X's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.